Antibody Information

General Information of This Antibody
Antibody ID
ANI0FNUNX
Antibody Name
Anti-CD22 mAb HB22.7
Antibody Type
Monoclonal antibody (mAb)
Antibody Subtype
Humanized IgG2a
Antigen Name
B-cell receptor CD22 (CD22)
  Antigen Info 
Each Antibody-drug Conjugate Related to This Antibody
Full Information of The Activity Data of The ADC(s) Related to This Antibody
HB22.7-SAP [Investigative]
 ADC Info 
Discovered Using Cell Line-derived Xenograft Model
Click To Hide/Show 10 Activity Data Related to This Level
Experiment 1 Reporting the Activity Date of This ADC [1]
Efficacy Data Tumor Growth Inhibition value (TGI) ≈ 2.67% (Day 18) Positive CD22 expression (CD22+++/++)
Method Description
Free hB22.7 (0.6 mg/kg) plus free sap (0.36 mg/kg).
In Vivo Model Raji NhLcells xenograft model
In Vitro Model EBV-related Burkitt lymphoma Raji cells CVCL_0511
Experiment 2 Reporting the Activity Date of This ADC [1]
Efficacy Data Tumor Growth Inhibition value (TGI) ≈ 13.33% (Day 18) Positive CD22 expression (CD22+++/++)
Method Description
HB22.7-sap (1 mg/kg).
In Vivo Model Raji NhLcells xenograft model
In Vitro Model EBV-related Burkitt lymphoma Raji cells CVCL_0511
Experiment 3 Reporting the Activity Date of This ADC [1]
Efficacy Data Tumor Growth Inhibition value (TGI)
100.00%
High CD22 expression (CD22+++)
Method Description
Nude mice were subcutaneously injected with 5 x 106 Raji cells. Twenty-four h later, designated as day 0, mice were randomly separated into three treatment groups (n = 810 per group) consisting of PBS, free HB22.7 (0.6 mg/kg) plus free SAP (0.36 mg/kg) and HB22.7-SAP (1 mg/kg).
In Vitro Model EBV-related Burkitt lymphoma Raji cells CVCL_0511
Experiment 4 Reporting the Activity Date of This ADC [1]
Efficacy Data Half Maximal Inhibitory Concentration (IC50)
1.00 ng/mL
Positive CD22 expression (CD22+++/++)
Method Description
The inhibitory activity of HB22.7-sap exerted a potent cytotoxic effect against all CD22+ NHL cell lines.
In Vitro Model Diffuse large B-cell lymphoma germinal center B-cell type DoHH2 cells CVCL_1179
Experiment 5 Reporting the Activity Date of This ADC [1]
Efficacy Data Half Maximal Inhibitory Concentration (IC50)
4.70 ng/mL
Positive CD22 expression (CD22+++/++)
Method Description
The inhibitory activity of HB22.7-sap exerted a potent cytotoxic effect against all CD22+ NHL cell lines.
In Vitro Model EBV-related Burkitt lymphoma Raji cells CVCL_0511
Experiment 6 Reporting the Activity Date of This ADC [1]
Efficacy Data Half Maximal Inhibitory Concentration (IC50)
7.60 ng/mL
Positive CD22 expression (CD22+++/++)
Method Description
The inhibitory activity of HB22.7-sap exerted a potent cytotoxic effect against all CD22+ NHL cell lines.
In Vitro Model Diffuse large B-cell lymphoma SU-DHL-4 cells CVCL_0539
Experiment 7 Reporting the Activity Date of This ADC [1]
Efficacy Data Half Maximal Inhibitory Concentration (IC50)
8.40 ng/mL
Positive CD22 expression (CD22+++/++)
Method Description
The inhibitory activity of HB22.7-sap exerted a potent cytotoxic effect against all CD22+ NHL cell lines.
In Vitro Model Burkitt lymphoma Ramos cells CVCL_0597
Experiment 8 Reporting the Activity Date of This ADC [1]
Efficacy Data Half Maximal Inhibitory Concentration (IC50) > 250.00 ng/mL Positive CD22 expression (CD22+++/++)
Method Description
The inhibitory activity of HB22.7-sap exerted a potent cytotoxic effect against all CD22+ NHL cell lines.
In Vitro Model Burkitt lymphoma Ramos cells CVCL_0597
Experiment 9 Reporting the Activity Date of This ADC [1]
Efficacy Data Half Maximal Inhibitory Concentration (IC50) > 250.00 ng/mL Negative CD22 expression (CC22-)
Method Description
The inhibitory activity of HB22.7-sap exerted a potent cytotoxic effect against all CD22+ NHL cell lines.
In Vitro Model T acute lymphoblastic leukemia Jurkat cells CVCL_0065
Experiment 10 Reporting the Activity Date of This ADC [1]
Efficacy Data Half Maximal Inhibitory Concentration (IC50)
519.00 ng/mL
Positive CD22 expression (CD22+++/++)
Method Description
The inhibitory activity of HB22.7-sap exerted a potent cytotoxic effect against all CD22+ NHL cell lines.
In Vitro Model Mantle cell lymphoma Granta-519 cells CVCL_1818
Revealed Based on the Cell Line Data
Click To Hide/Show 6 Activity Data Related to This Level
Experiment 1 Reporting the Activity Date of This ADC [1]
Efficacy Data Half Maximal Inhibitory Concentration (IC50)
1.00 ng/mL
Moderate CD22 expression (CD22++)
Method Description
The in vitro cytotoxicity of HB22.7-SAP was evaluated using an MTS assay. Cells were seeded in 96-well plates at a density of 1 x104 cells/well in 90 uL media. HB22.7-SAP was serially diluted with media and 10 L of each dilution was added to the appropriate well and incubated continuously for 72 h.
In Vitro Model Diffuse large B-cell lymphoma SU-DHL-4 cells CVCL_0539
Experiment 2 Reporting the Activity Date of This ADC [1]
Efficacy Data Half Maximal Inhibitory Concentration (IC50)
1.60 ng/mL
Moderate CD22 expression (CD22++)
Method Description
The in vitro cytotoxicity of HB22.7-SAP was evaluated using an MTS assay. Cells were seeded in 96-well plates at a density of 1 1 x104 cells/well in 90 uL media. HB22.7-SAP was serially diluted with media and 10 L of each dilution was added to the appropriate well and incubated continuously for 72 h.
In Vitro Model Diffuse large B-cell lymphoma germinal center B-cell type DoHH2 cells CVCL_1179
Experiment 3 Reporting the Activity Date of This ADC [1]
Efficacy Data Half Maximal Inhibitory Concentration (IC50)
4.70 ng/mL
High CD22 expression (CD22+++)
Method Description
The in vitro cytotoxicity of HB22.7-SAP was evaluated using an MTS assay. Cells were seeded in 96-well plates at a density of 1x104 cells/well in 90 L media. HB22.7-SAP was serially diluted with media and 10 L of each dilution was added to the appropriate well and incubated continuously for 72 h.
In Vitro Model EBV-related Burkitt lymphoma Raji cells CVCL_0511
Experiment 4 Reporting the Activity Date of This ADC [1]
Efficacy Data Half Maximal Inhibitory Concentration (IC50)
7.60 ng/mL
Moderate CD22 expression (CD22++)
Method Description
The in vitro cytotoxicity of HB22.7-SAP was evaluated using an MTS assay. Cells were seeded in 96-well plates at a density of 1x104 cells/well in 90 L media. HB22.7-SAP was serially diluted with media and 10 L of each dilution was added to the appropriate well and incubated continuously for 72 h.
In Vitro Model Mantle cell lymphoma Granta-519 cells CVCL_1818
Experiment 5 Reporting the Activity Date of This ADC [1]
Efficacy Data Half Maximal Inhibitory Concentration (IC50)
8.40 ng/mL
High CD22 expression (CD22+++)
Method Description
The in vitro cytotoxicity of HB22.7-SAP was evaluated using an MTS assay. Cells were seeded in 96-well plates at a density of 1x104 cells/well in 90 L media. HB22.7-SAP was serially diluted with media and 10 L of each dilution was added to the appropriate well and incubated continuously for 72 h.
In Vitro Model Burkitt lymphoma Ramos cells CVCL_0597
Experiment 6 Reporting the Activity Date of This ADC [1]
Efficacy Data Half Maximal Inhibitory Concentration (IC50) > 2500.00 ng/mL Negative CD22 expression (CC22-)
Method Description
The in vitro cytotoxicity of HB22.7-SAP was evaluated using an MTS assay. Cells were seeded in 96-well plates at a density of 1 x104 cells/well in 90 uL media. HB22.7-SAP was serially diluted with media and 10 uL of each dilution was added to the appropriate well and incubated continuously for 72 h.
In Vitro Model T acute lymphoblastic leukemia Jurkat cells CVCL_0065
References
Ref 1 Efficacy and toxicity of a CD22-targeted antibody-saporin conjugate in a xenograft model of non-Hodgkin's lymphoma. Oncoimmunology. 2012 Dec 1;1(9):1469-1475.

If you find any error in data or bug in web service, please kindly report it to Dr. Shen et al.